Dr Pierre Scotney is a Senior Scientist in Research at CSL Limited, as well as an Honorary Member of the University Melbourne at the Bio21 Institute. He has extensive experience in the pharmaceutical and biotechnology sector having worked at Roche Pharmaceuticals, Zenyth Therapeutics and CSL Limited. He completed his PhD in biochemistry at the University of Bristol (UK) in 1999 and came to Australia to undertake postdoctoral research at St. Vincent’s Institute of Medical Research (Melbourne). In 2001 he began investigating the biology of Vascular Endothelial Growth Factors (VEGFs) with an industry-partnered post-doctoral fellowship at the University of Melbourne and biotechnology company Zenyth Therapeutics (then Amrad Corporation). In 2004 he joined Zenyth to continue the research and develop novel therapeutics that targeted VEGFs. In November 2006 Zenyth Therapeutics was acquired by CSL Limited and Dr Scotney was appointed as a Senior Scientist, Research, located at the Bio21 Institute. He currently works with a large multidisciplinary team focused on the discovery and development of new recombinant antibody and protein-based medicines to treat serious human disease. Dr Scotney has published in peer-reviewed publications and has inventorship on patent filings.
Abstracts this author is presenting: